81 related articles for article (PubMed ID: 20440617)
1. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of human aminopeptidase N.
Hausheer FH; Parker AR; Petluru PN; Jair KW; Chen S; Huang Q; Chen X; Ayala PY; Shanmugarajah D; Kochat H
Cancer Chemother Pharmacol; 2011 Feb; 67(2):381-91. PubMed ID: 20440617
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic study of BNP7787-mediated cisplatin nephroprotection: modulation of gamma-glutamyl transpeptidase.
Hausheer FH; Shanmugarajah D; Leverett BD; Chen X; Huang Q; Kochat H; Petluru PN; Parker AR
Cancer Chemother Pharmacol; 2010 Apr; 65(5):941-51. PubMed ID: 19714332
[TBL] [Abstract][Full Text] [Related]
3. Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
Verschraagen M; Boven E; Torun E; Hausheer FH; Bast A; van der Vijgh WJ
Biochem Pharmacol; 2004 Aug; 68(3):493-502. PubMed ID: 15242815
[TBL] [Abstract][Full Text] [Related]
4. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy.
Pendyala L; Schwartz G; Smith P; Zdanowicz J; Murphy M; Hausheer F
Cancer Chemother Pharmacol; 2003 May; 51(5):376-84. PubMed ID: 12682786
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic behaviour of the chemoprotectants BNP7787 and mesna after an i.v. bolus injection in rats.
Verschraagen M; Boven E; Torun E; Erkelens CA; Hausheer FH; van der Vijgh WJ
Br J Cancer; 2004 Apr; 90(8):1654-9. PubMed ID: 15083199
[TBL] [Abstract][Full Text] [Related]
6. Analysis of BNP7787 thiol-disulfide exchange reactions in phosphate buffer and human plasma using microscale electrochemical high performance liquid chromatography.
Shanmugarajah D; Ding D; Huang Q; Chen X; Kochat H; Petluru PN; Ayala PY; Parker AR; Hausheer FH
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Apr; 877(10):857-66. PubMed ID: 19278906
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
[TBL] [Abstract][Full Text] [Related]
8. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report.
Verschraagen M; Boven E; Zegers I; Hausheer FH; Van der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):525-9. PubMed ID: 12750838
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.
Verschraagen M; Zwiers TH; Torun E; Donker MG; Reinhoud NJ; Van der Vijgh WJ
J Pharm Sci; 2003 May; 92(5):1040-50. PubMed ID: 12712424
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of BNP7787 in human renal proximal tubule cells.
Hausheer FH; Ding D; Shanmugarajah D; Leverett BD; Huang Q; Chen X; Kochat H; Ayala PY; Petluru PN; Parker AR
J Pharm Sci; 2011 Sep; 100(9):3977-84. PubMed ID: 21344411
[TBL] [Abstract][Full Text] [Related]
12. The chemical reactivity of BNP7787 and its metabolite mesna with the cytostatic agent cisplatin: comparison with the nucleophiles thiosulfate, DDTC, glutathione and its disulfide GSSG.
Verschraagen M; Kedde MA; Hausheer FH; Van Der Vijgh WJ
Cancer Chemother Pharmacol; 2003 Jun; 51(6):499-504. PubMed ID: 12715205
[TBL] [Abstract][Full Text] [Related]
13. Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents.
Hausheer FH; Kanter P; Cao S; Haridas K; Seetharamulu P; Reddy D; Petluru P; Zhao M; Murali D; Saxe JD; Yao S; Martinez N; Zukowski A; Rustum YM
Semin Oncol; 1998 Oct; 25(5):584-99. PubMed ID: 9783598
[TBL] [Abstract][Full Text] [Related]
14. BNP7787-mediated modulation of paclitaxel- and cisplatin-induced aberrant microtubule protein polymerization in vitro.
Parker AR; Petluru PN; Wu M; Zhao M; Kochat H; Hausheer FH
Mol Cancer Ther; 2010 Sep; 9(9):2558-67. PubMed ID: 20807779
[TBL] [Abstract][Full Text] [Related]
15. Enzymatic and non-enzymatic mechanisms of dimesna metabolism.
Cutler MJ; Velenosi TJ; Bodalia A; House AA; Urquhart BL; Freeman DJ
Amino Acids; 2015 Mar; 47(3):511-23. PubMed ID: 25488427
[TBL] [Abstract][Full Text] [Related]
16. Aminopeptidase N mediates the utilization of the GSH precursor CysGly by cultured neurons.
Dringen R; Gutterer JM; Gros C; Hirrlinger J
J Neurosci Res; 2001 Dec; 66(5):1003-8. PubMed ID: 11746430
[TBL] [Abstract][Full Text] [Related]
17. Role of cysteine S-conjugate beta-lyase in the metabolism of cisplatin.
Zhang L; Hanigan MH
J Pharmacol Exp Ther; 2003 Sep; 306(3):988-94. PubMed ID: 12750429
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of gamma-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity.
Hanigan MH; Gallagher BC; Taylor PT; Large MK
Cancer Res; 1994 Nov; 54(22):5925-9. PubMed ID: 7954424
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of urotoxic actions of cyclophosphamide and ifosfamide by dimesna (preliminary communication) (author's transl)].
Brock N; Stekar J
Arzneimittelforschung; 1982; 32(5):486-7. PubMed ID: 6809014
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway.
Wainford RD; Weaver RJ; Stewart KN; Brown P; Hawksworth GM
Toxicology; 2008 Jul; 249(2-3):184-93. PubMed ID: 18583013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
